Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DUBLIN, Ireland, Feb. 24, 2017 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2016 on Tuesday, March 14, 2017. The Company has scheduled a conference call for that same day, Tuesday, March 14, 2017 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |||||||||
| International: | 1-412-317-6581 | |||||||||
| Conference ID #: | 10102284 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/19990
A replay of the call can be accessed until March 21, 2017 by dialing:
| USA: | 1-877-344-7529 | ||||||||||
| International: | 1-412-317-0088 | ||||||||||
| Conference ID #: | 10102284 | ||||||||||
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/19990
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
